中國稀土(00769.HK)擬折讓約16.9%發行4875萬股 淨籌1550萬港元
格隆匯4月16日丨中國稀土(00769.HK)公吿,於2025年4月16日,公司與認購人訂立認購協議,據此,認購人有條件同意認購,而公司有條件同意按認購價每股認購股份0.32港元配發及發行合共4875萬股股份。認購股份將根據一般授權配發及發行。
認購股份相當於於本公吿日期公司現有已發行股本2.1%;認購價較(i)於2025年4月16日(即認購協議日期)於聯交所所報收市價每股0.385港元折讓約16.9%;認購事項所得款項總額及所得款項淨額將分別約為1560萬港元及1550萬港元。所得款項淨額擬用作集團營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.